Harrow Reports Record Q3 2026 Revenue of $99.3M and Updates Full-Year Guidance

Harrow, Inc. announced its financial results for the third quarter ended September 30, 2026, reporting record revenue and updated guidance for the full year. For the three months ended September 30, 2026, the company reported total revenue of $99.3 million, a 41% increase from the previous quarter and a 39% increase compared to the third quarter of 2025. The company’s branded revenue reached $83.5 million, representing approximately 84% of total revenue, which was up 62% year over year.

On the income statement, Harrow recorded GAAP net income of $9.8 million for the quarter. This figure included a $5.0 million gain from a litigation settlement. In comparison, the company reported a net loss of $17.3 million in the second quarter of 2026 and net income of $1.0 million in the third quarter of 2025. Adjusted EBITDA, a non-GAAP measure, was $21.2 million for the quarter, compared to a loss of $1.2 million in the prior quarter and $22.8 million in the same period last year.

As of September 30, 2026, Harrow held cash and cash equivalents of $75.3 million. The company reaffirmed its full-year 2026 revenue guidance of $350 million to $365 million. However, it updated its full-year Adjusted EBITDA guidance to more than $40 million. This updated outlook includes an expectation of more than $33 million in Adjusted EBITDA for the fourth quarter. The company noted that this revised guidance reflects operating shortfalls in the first half of the year and increased spending related to the G-MELT NDA submission and the integration of the TYRVAYA acquisition.

Commercial highlights from the quarter included record revenue for the VEVYE product line of $39.7 million, up 75% year over year. IHEEZO revenue was $25.3 million, and TRIESENCE revenue reached $10.7 million, marking the highest quarterly revenue under Harrow’s ownership. Additionally, Harrow completed the acquisition of TYRVAYA on October 1, 2026, adding a branded dry eye treatment to its portfolio. The company also launched HarrowRx on November 1, 2026, a platform designed to streamline the prescription process for its products.